Company intelligence / Profile preview
Onconic Therapeutics Inc.
Seoul, South Koreaonconic.co.kr ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Onconic Therapeutics has achieved regulatory approval in South Korea for its lead product ZacuCorrection—a next-generation potassium competitive acid blocker—for gastroesophageal reflux disease. Clinical data show high efficacy rates compared to standard of care. The company also has multiple clinical-stage assets targeting oncology and gastrointestinal disorders, including a PARP inhibitor in early-phase trials.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small moleculesPotassium competitive acid blockers (P-CABs)PARP inhibitorsDDR inhibitorsImmuno-oncology agents
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Livzon Pharmaceutical Group—license agreement for China rights to ZacuCorrection ($127.5M deal)
Beyond the preview
Go deeper on Onconic Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Onconic Therapeutics Inc..